



NEPHROCARE HEALTH SERVICES LIMITED



(Please scan this QR code to view the Prospectus)

Our Company was incorporated as "Nephrocare Health Services Private Limited", a private limited company under the Companies Act, 1956, at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh ("RoC Andhra Pradesh") on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by our Board and Shareholders, respectively, our Company was converted into a public limited company and consequently, the name of our Company was changed to "Nephrocare Health Services Limited" with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. See "History and Certain Corporate Matters – Changes in the Registered Office" on page 350 of the prospectus dated December 12, 2025 ("Prospectus") filed with the Registrar of Companies, Telangana at Hyderabad ("RoC").

Registered and Corporate Office: 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad - 500 081, Telangana, India;
Contact Person: Kishore Kathri, Company Secretary and Compliance Officer; Tel: +91 40 4240 8039; E-mail: cs@nephroplus.com; Website: www.nephroplus.com; Corporate Identity Number: U85100TG2009PLC066359

PROMOTERS OF OUR COMPANY: VIKRAM VUPPALA, BESSEMER VENTURE PARTNERS TRUST, EDORAS INVESTMENT HOLDINGS PTE. LTD., HEALTHCARE PARENT LIMITED, INVESTCORP PRIVATE EQUITY FUND II AND INVESTCORP GROWTH OPPORTUNITY FUND

Our Company has filed the Prospectus dated December 12, 2025 with Registrar of Companies, Telangana at Hyderabad and the Equity Shares (as defined below) are proposed to be listed on the main board platform of the Stock Exchanges and the trading will commence on or about Wednesday, December 17, 2025.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 18,943,020 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF NEPHROCARE HEALTH SERVICES LIMITED ("OUR COMPANY" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹460^{*} PER EQUITY SHARE FACE VALUE OF ₹2 (INCLUDING A SECURITIES PREMIUM OF ₹458 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹8,710.48 MILLION ("OFFER") COMPRISING A FRESH ISSUE OF 7,689,918 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹3,534.05 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF 11,253,102 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING TO ₹5,176.43 MILLION, COMPRISING AN OFFER FOR SALE OF 1,521,728 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹699.99 MILLION BY INVESTCORP PRIVATE EQUITY FUND II AND 1,604,907 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹738.26 MILLION BY HEALTHCARE PARENT LIMITED AND 147,765 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹67.97 MILLION BY INVESTCORP GROWTH OPPORTUNITY FUND AND 2,888,911 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹1,328.90 MILLION BY EDORAS INVESTMENT HOLDINGS PTE. LTD. ("PROMOTER SELLING SHAREHOLDERS") AND 121,985 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹56.11 MILLION BY INVESTCORP INDIA PRIVATE EQUITY OPPORTUNITY LIMITED AND 3,089,663 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹1,421.24 MILLION BY INTERNATIONAL FINANCE CORPORATION AND 1,433,468 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹659.40 MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9 AND 444,675 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹204.55 MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 10 ("OTHER SELLING SHAREHOLDERS") AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE"). THE OFFER CONSTITUTED 18.88% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

* A discount of ₹41 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.

ANCHOR INVESTOR OFFER PRICE: ₹460 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

OFFER PRICE: ₹460 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

THE OFFER PRICE IS 230 TIMES THE FACE VALUE OF THE EQUITY SHARES.

The Price to Earnings Ratio ("P/E") based on Diluted EPS For Fiscal 2025 for the Company at the Upper end of Price Band is 57.42 Times and at the Lower end of the Price band is 54.68 Times.

RISK TO INVESTORS

(For details, refer to section titled "Risk Factors" on page 49 of the Prospectus)

- Our reliance on captive clinics^{*}:** We derive a portion of our revenue from operations from our captive clinics, and such captive clinics accounted for 36.51%, 43.30%, 51.96% and 62.23% of our revenue from operations in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023 respectively.
**Defined as the dialysis clinics operated within private hospital premises under contractual arrangement.*
- Our reliance on public private partnership ("PPP") contracts:** We operate a number of our dialysis clinics under PPP contracts awarded by government agencies through a competitive bidding process. Such contracts accounted for 30.96%, 32.62%, 29.24% and 22.39% of our revenue from operations in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023 respectively.
- Risks related to high international operations:** Our current and future international operations, including in the Philippines, Uzbekistan, and Nepal, exposes us to management, legal, tax, political, and economic risks that could adversely affect our business, financial condition, results of operations, cash flows, and prospects. In the six months period ended September 30, 2025, Fiscal 2025, 2024 and 2023, we generated ₹ 1,892.18 million, ₹ 2,403.10 million, ₹ 1,346.16 million and ₹ 511.84 million, respectively, from our revenue from operations outside India that accounted for 39.96%, 31.79%, 23.78%, and 11.70%, respectively, of our revenue from operations in such periods.
- Our reliance on healthcare professionals:** Our performance and growth strategy depends substantially on our ability to attract and retain experienced healthcare professionals. Our healthcare professional fees accounted for 11.46%, 13.24%, 10.95% and 6.87% of our total expenses in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. Further the attrition rate of our nephrologists, including doctors, physicians on duty and medical directors, was 27.68%, 53.05%, 61.23% and 29.39% in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023, respectively.
- Risks in relation to expansion:** As of September 30, 2025, we operated 468 clinics in 21 States and four Union Territories and 288 cities in India, six clinics across six cities in Nepal, 41 clinics across 30 cities in Philippines and four clinics across three cities in the Republic of Uzbekistan. Expansion into new geographic regions subjects us to various challenges, including those relating to our lack of familiarity with the culture, governmental agencies, local laws and regulations and economic conditions of these new regions, language barriers, difficulties in staffing and managing such operations, and the lack of brand recognition and reputation in such regions.
- Risks in relation to business interruption at our dialysis clinics:** As of September 30, 2025, we operated 519 dialysis clinics, 272 of those clinics are captive clinics, 67 are operated by us independently as standalone clinics and 180 of those clinics are operated under PPP arrangements. Any risk of business interruption at our dialysis clinics on account of any internal factors could have a material adverse impact on our business operations and results of operations.
- Operational, reputational, and legal risks associated with our participation in public-private partnership projects:** Our operations under the PPP contracting mode expose us to risk of contract termination and potential blacklisting by public health authorities in the event of non-performance or failure to deliver services in accordance with contractual obligations. For instance, in 2014, our Company was debarred from participating in a government tender for one year by the Government of the National Capital Territory of Delhi, following the withdrawal of our consortium partner after the issuance of the notice of award.
- Risks related to Price Band:** Our revenue from operations for Fiscal 2025 was ₹ 7,558.12 million and our profit for the year for Fiscal 2025 was ₹ 670.96 million, respectively. The table below provides details of our enterprise value to EBITDA ratio, price to earnings ratio and market capitalization to revenue from operations for Fiscal 2025:

Particulars	Ratio vis-à-vis Floor Price		Ratio vis-à-vis Cap Price	
	(In multiples, unless otherwise specified)			
Enterprise value to EBITDA	27.45		28.79	
Market capitalization to revenue from operations	5.92		6.22	
Price-to-earnings ratio	52.88		55.53	

BID/OFFER PERIOD:

**ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON:
TUESDAY, 9 DECEMBER, 2025**

BID/OFFER OPENED ON: WEDNESDAY, 10 DECEMBER, 2025

BID/ OFFER CLOSED ON: FRIDAY, 12 DECEMBER, 2025

The Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer was made through the Book Building Process in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer was made available for allocation on a proportionate basis to QIBs (the "QIB Portion"), provided that our Company, in consultation with the BRLMs, allocated 60% of the QIB Portion to Anchor Investors and the basis of such allocation was on a discretionary basis by our Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which one-third was reserved for domestic Mutual Funds. However, effective December 1, 2025, in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Third Amendment) Regulations, 2025, of the Anchor Investor Portion, (i) 33.33% was available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds. In the event of under-subscription in (ii) above, the allocation was made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares was added to the remaining QIB Portion (other than Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds. Further, not less than 15% of the Net Offer was made available for allocation to NIIIs ("Non-Institutional Category") of which one-third of the Non-Institutional Category was made available for allocation to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and two-thirds of the Non-Institutional Category was made available for allocation to Bidders with an application size of more than ₹1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Category was allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations. Further, not less than 35% of the Net Offer was available for allocation to RIIs ("Retail Category"), in accordance with the SEBI ICDR Regulations. All Bidders, other than the Anchor Investors, were required to mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process, providing details of their respective bank accounts (including UPI ID (defined hereinafter) for UPI Bidders (defined hereinafter) in which the Bid amount was blocked by the Self Certified Syndicate Banks ("SCSBs") or the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors were not permitted to participate in the Anchor Investor Portion through the ASBA process. Further, Equity Shares were allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion. For further details, see "Offer Procedure" beginning on page 581 of the Prospectus.

The bidding for Anchor Investors opened and closed on Tuesday, December 9, 2025. The company received 14 Anchor Investor Application Forms from 13 Anchor Investors (including 5 domestic mutual funds through 6 Mutual Fund scheme) for 5,715,424 Equity Shares. The Anchor investor price was finalized at ₹ 460 per Equity Share. A total of 5,657,919 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 2,602,642,740/-.

The Offer received 454,728 applications for 192,687,584 Equity Shares (prior to rejections) resulting in 10.17 times subscription. The details of the applications received in the Offer from various categories are as under: (before rejections):

Sl. No.	Category	No. of Applications received*	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Retail Individual Investors	397,073	15,554,656	6,600,907	2.36	7,152,960,672.00
B	Non-Institutional Investors - More than ₹0.20 million up to ₹1.00 million	27,927	12,801,696	942,987	13.58	5,886,803,904.00
C	Non-Institutional Investors - Above ₹1.00 million	25,929	57,587,936	1,885,973	30.53	26,490,373,760.00
D	Eligible Employees	3,723	235,264	83,532	2.82	98,544,032.00
E	Qualified Institutional Bidders (excluding Anchor Investors)	62	100,792,608	3,771,946	26.72	46,364,599,680.00
F	Anchor Investors	14	5,715,424	5,657,919	1.01	2,629,095,040.00
Total		454,728	192,687,584	18,943,264	10.17	88,622,377,088.00

* This excludes 3,061 applications for 118,880 Equity Shares aggregating to ₹54,794,208/- from Retail Individual & HNI Individuals which were not in bid book but which were banked.

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/Offer Closing Date and as at different Bid prices is as under:

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	438	102,240	0.05	102,240	0.05
2	439	5,792	0.00	108,032	0.06
3	440	30,624	0.02	138,656	0.07
4	441	2,208	0.00	140,864	0.07
5	442	1,568	0.00	142,432	0.07
6	443	992	0.00	143,424	0.07
7	444	1,632	0.00	145,056	0.07
8	445	8,672	0.00	153,728	0.08
9	446	576	0.00	154,304	0.08
10	447	928	0.00	155,232	0.08
11	448	3,392	0.00	158,624	0.08
12	449	2,240	0.00	160,864	0.08
13	450	30,912	0.02	191,776	0.10
14	451	1,216	0.00	192,992	0.10

Continued to next page...

Continued from previous page.

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
15	452	672	0.00	193,664	0.10
16	453	160	0.00	193,824	0.10
17	454	160	0.00	193,984	0.10
18	455	5,568	0.00	199,552	0.10
19	456	1,024	0.00	200,576	0.10
20	457	1,568	0.00	202,144	0.10
21	458	15,872	0.01	218,016	0.11
22	459	16,672	0.01	234,688	0.12
23	460	176,227,968	90.46	176,462,656	90.58
	CUTOFF	18,349,856	9.42	194,812,512	100.00
		194,812,512	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on December 15, 2025.

A. Allotment to Retail Individual Investors (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price or at the Offer Price of ₹ 460 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 2.29 times. The total number of Equity Shares Allotted in Retail Portion is 6,601,778 Equity Shares (Including Spilled over of 871 Equity Shares from Employee category) to 2,06,305 successful Retail Individual Investors. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	32	359,575	93.11	11,506,400	76.02	32	398 : 745	6,147,072
2	64	13,530	3.50	865,920	5.72	32	39 : 73	231,296
3	96	4,209	1.09	404,064	2.66	32	39 : 73	71,936
4	128	1,819	0.47	232,832	1.53	32	39 : 73	31,104
5	160	1,462	0.38	233,920	1.54	32	39 : 73	24,992
6	192	674	0.17	129,408	0.85	32	39 : 73	11,520
7	224	838	0.22	187,712	1.24	32	39 : 73	14,336
8	256	216	0.06	55,296	0.36	32	115 : 216	3,680
9	288	130	0.03	37,440	0.24	32	69 : 130	2,208
10	320	593	0.15	189,760	1.25	32	39 : 73	10,144
11	352	96	0.02	33,792	0.22	32	51 : 96	1,632
12	384	119	0.03	45,696	0.30	32	64 : 119	2,048
13	416	2,913	0.75	1,211,808	8.00	32	39 : 73	49,792
	64-416	0	0.00	-	0.00	1	18 : 14209	18
	TOTAL	386,174	100.00	15,134,048	100.00			6,601,778

Notes: 1 additional Share has been allotted to 18 Allottees from amongst 14,209 Successful Allottees from the categories 64-416 (i.e. Excluding successful allottees from Category 32) in the ratio of 18:14209

B. Allotment to Non-Institutional Investors (More than ₹0.20 million Up to ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹0.20 million Up to ₹1.00 million), who have bid at the Offer Price of ₹ 460 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 13.33906 times. The total number of Equity Shares allotted in this category is 943,112 Equity Shares (includes spilled over of 125 Equity Shares from Employee Category) to 2,105 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	448	26,664	97.14	11,945,472	94.95	448	26 : 339	916,160
2	480	237	0.86	113,760	0.90	449	18 : 237	8,082
3	512	46	0.17	23,552	0.19	449	4 : 46	1,796
4	544	28	0.10	15,232	0.12	449	2 : 28	898
5	576	20	0.07	11,520	0.09	449	2 : 20	898
6	608	15	0.05	9,120	0.07	449	1 : 15	449
7	640	63	0.23	40,320	0.32	449	5 : 63	2,245
8	672	33	0.12	22,176	0.18	449	3 : 33	1,347
9	704	4	0.01	2,816	0.02	449	0 : 4	0
10	736	7	0.03	5,152	0.04	449	1 : 7	449
11	768	2	0.01	1,536	0.01	449	0 : 2	0
12	800	10	0.04	8,000	0.06	449	1 : 10	449
13	832	5	0.02	4,160	0.03	449	0 : 5	0
14	864	15	0.05	12,960	0.10	449	1 : 15	449
15	896	35	0.13	31,360	0.25	449	3 : 35	1,347
16	928	5	0.02	4,640	0.04	449	0 : 5	0
17	960	11	0.04	10,560	0.08	449	1 : 11	449
18	992	9	0.03	8,928	0.07	449	1 : 9	449
19	1,024	18	0.07	18,432	0.15	449	1 : 18	449
20	1,056	123	0.45	129,888	1.03	449	9 : 123	4,041
21	1,088	15	0.05	16,320	0.13	449	1 : 15	449
22	1,120	5	0.02	5,600	0.04	449	0 : 5	0
23	1,152	5	0.02	5,760	0.05	449	0 : 5	0
24	1,280	7	0.03	8,960	0.07	449	1 : 7	449
25	1,312	2	0.01	2,624	0.02	449	0 : 2	0
26	1,344	4	0.01	5,376	0.04	449	0 : 4	0
27	1,376	6	0.02	8,256	0.07	449	0 : 6	0
28	1,440	3	0.01	4,320	0.03	449	0 : 3	0
29	1,504	4	0.01	6,016	0.05	449	0 : 4	0
30	1,536	2	0.01	3,072	0.02	449	0 : 2	0
31	1,600	3	0.01	4,800	0.04	449	0 : 3	0
32	1,696	1	0.00	1,696	0.01	449	0 : 1	0
33	1,728	4	0.01	6,912	0.05	449	0 : 4	0
34	1,760	2	0.01	3,520	0.03	449	0 : 2	0
35	1,792	4	0.01	7,168	0.06	449	0 : 4	0
36	1,984	1	0.00	1,984	0.02	449	0 : 1	0
37	2,016	2	0.01	4,032	0.03	449	0 : 2	0
38	2,080	1	0.00	2,080	0.02	449	0 : 1	0
39	2,112	1	0.00	2,112	0.02	449	0 : 1	0
40	2,144	28	0.10	60,032	0.48	449	2 : 28	898
	Non Allottees	-	0.00	-	0.00	449	3 : 66	1,347
	480-2144	-	0.00	-	0.00	1	12 : 60	12
	TOTAL	27,450	100.00	12,580,224	100.00			943,112

Notes:
(1) 1 (One) lot of 448 shares has been allotted to all the 66 Non Allottees Applicants in Categories with ZERO/NO Allotment in the ratio of 3:66
(2) 1 additional Share has been allotted to all 60 Successful Allottees from the categories 480 to 2,144 (i.e., excluding successful allottees from Category 448) in the ratio of 1 : 1
(3) 1 additional Share has been allotted to 12 Successful Allottees from the categories 480 to 2,144 (i.e. excluding successful allottees from Category 448) in the ratio of 12:60

C. Allotment to Non-Institutional Investors (more than ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹1.00 million), who have bid at the Offer Price of ₹ 460 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 30.42341 times. The total number of Equity Shares allotted in this category is 1,886,222 Equity Shares (includes spilled over of 249 Equity Shares from Employee Category) to 4,210 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	2,176	25,284	97.86	55,017,984	95.87	448	95 : 583	1,845,760
2	2,208	155	0.60	342,240	0.60	448	25 : 155	11,200
3	2,240	116	0.45	259,840	0.45	448	19 : 116	8,512
4	2,272	15	0.06	34,080	0.06	448	2 : 15	896
5	2,304	20	0.08	46,080	0.08	448	3 : 20	1,344
6	2,336	28	0.11	65,408	0.11	448	5 : 28	2,240
7	2,368	13	0.05	30,784	0.05	448	2 : 13	896
8	2,400	25	0.10	60,000	0.10	448	4 : 25	1,792
9	2,432	12	0.05	29,184	0.05	448	2 : 12	896
10	2,496	4	0.02	9,984	0.02	448	1 : 4	448
11	2,528	1	0.00	2,528	0.00	448	0 : 1	0
12	2,560	7	0.03	17,920	0.03	448	1 : 7	448
13	2,592	4	0.02	10,368	0.02	448	1 : 4	448
14	2,624	6	0.02	15,744	0.03	448	1 : 6	448
15	2,656	5	0.02	13,280	0.02	448	1 : 5	448
16	2,688	4	0.02	10,752	0.02	448	1 : 4	448
17	2,912	6	0.02	17,472	0.03	448	1 : 6	448
18	2,944	6	0.02	17,664	0.03	448	1 : 6	448
19	3,008	4	0.02	12,032	0.02	448	1 : 4	448
20	3,040	4	0.02	12,160	0.02	448	1 : 4	448
21	3,072	8	0.03	24,576	0.04	448	1 : 8	448
22	3,200	19	0.07	60,800	0.11	448	3 : 19	1,344
23	3,232	1	0.00	3,232	0.01	448	0 : 1	0
24	3,264	1	0.00	3,264	0.01	448	0 : 1	0
25	3,296	1	0.00	3,296	0.01	448	0 : 1	0
26	3,520	1	0.00	3,520	0.01	448	0 : 1	0
27	3,680	1	0.00	3,680	0.01	448	0 : 1	0
28	3,712	1	0.00	3,712	0.01	448	0 : 1	0
29	3,840	3	0.01	11,520	0.02	448	0 : 3	0
30	4,000	2	0.01	8,000	0.01	448	0 : 2	0
31	4,096	4	0.02	16,384	0.03	448	1 : 4	448
32	4,160	2	0.01	8,320	0.01	448	0 : 2	0
33	4,352	5	0.02	21,760	0.04	448	1 : 5	448
34	4,416	1	0.00	4,416	0.01	448	0 : 1	0
35	4,480	5	0.02	22,400	0.04	448	1 : 5	448
36	4,672	4	0.02	18,688	0.03	448	1 : 4	448

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
37	4,992	1	0.00	4,992	0.01	448	0 : 1	0
38	5,056	1	0.00	5,056	0.01	448	0 : 1	0
39	5,088	1	0.00	5,088	0.01	448	0 : 1	0
40	5,376	1	0.00	5,376	0.01	448	0 : 1	0
41	5,440	3	0.01	16,320	0.03	448	0 : 3	0
42	5,696	4	0.02	22,784	0.04	448	1 : 4	448
43	5,760	1	0.00	5,760	0.01	448	0 : 1	0
44	5,824	4	0.02	23,296	0.04	448	1 : 4	448
45	5,984	1	0.00	5,984	0.01	448	0 : 1	0
46	6,400	1	0.00	6,400	0.01	448	0 : 1	0
47	6,528	2	0.01	13,056	0.02	448	0 : 2	0
48	7,200	1	0.00	7,200	0.01	448	0 : 1	0
49	7,776	4	0.02	31,104	0.05	448	1 : 4	448
50	7,840	1	0.00	7,840	0.01	448	0 : 1	0
51	8,800	1	0.00	8,800	0.02	448	0 : 1	0
52	8,960	1	0.00	8,960	0.02	448	0 : 1	0
53	9,184	1	0.00	9,184	0.02	448	0 : 1	0
54	10,240	1	0.00	10,240	0.02	448	0 : 1	0
55	10,560	1	0.00	10,560	0.02	448	0 : 1	0
56	10,784	1	0.00	10,784	0.02	448	0 : 1	0
57	10,848	4	0.02	43,392	0.08	448	1 : 4	448
58	11,200	1	0.00	11,200	0.02	448	0 : 1	0
59	11,968	1	0.00	11,968	0.02	448	0 : 1	0
60	12,800	1	0.00	12,800	0.02	448	0 : 1	0
61	13,056	5	0.02	65,280	0.11	448	1 : 5	448
62	13,984	1	0.00	13,984	0.02	448	0 : 1	0